坎格瑞洛在合并心源性休克或心脏骤停后接受经皮冠状动脉介入治疗的危重症患者中的应用:系统评价与荟萃分析
该系统评价与荟萃分析(PROSPERO CRD420251126926)检索PubMed、Embase和Cochrane图书馆至2025年8月31日,纳入12项研究共4537例接受PCI的心源性休克或心脏骤停后患者,比较辅助坎格瑞洛与口服P2Y12抑制剂。坎格瑞洛组全因死亡率降低(RR 0.90;95%CI 0.82–0.98),其效应在心源性休克亚组显著(RR 0.86;95%CI 0.78–0.96),心脏骤停亚组未达显著(RR 0.94;95%CI 0.74–1.18);TIMI 3级血流达成率更高(RR 1.14;95%CI 1.01–1.29)。心血管死亡、支架血栓、心肌梗死、卒中无显著差异;总体大出血未显著增加(RR 1.37;95%CI 0.95–1.97),但在对照研究中风险相对升高(RR 1.50;95%CI 1.10–2.05)。作者认为,在口服P2Y12抑制剂给药不可行时,坎格瑞洛可作为有价值的替代选择,但总体临床获益尚待大规模随机试验确认。
要点
- 合并心源性休克接受PCI者,辅助坎格瑞洛较常规治疗降低全因死亡率(RR 0.90;95%CI 0.82–0.98),心源性休克亚组RR 0.86(95%CI 0.78–0.96)。
- 心脏骤停后接受PCI者,坎格瑞洛对全因死亡率无显著影响(RR 0.94;95%CI 0.74–1.18)。
- 坎格瑞洛组PCI后TIMI 3级血流达成率更高(RR 1.14;95%CI 1.01–1.29)。
- 总体大出血未显著增加(RR 1.37;95%CI 0.95–1.97),但对照研究中大出血风险相对升高(RR 1.50;95%CI 1.10–2.05)。
- 作者认为,口服P2Y12抑制剂不可行时坎格瑞洛可作为有价值的替代选择,总体临床获益待大规模随机试验确认。
适用人群与场景
- 接受经皮冠状动脉介入治疗(PCI)的心源性休克(CS)或心脏骤停后(CA)危重症患者。
- 亚组包括使用机械循环支持的心源性休克患者、院外心脏骤停患者及接受目标温度管理的心脏骤停患者。
研究设计与关键结果
- 系统评价与荟萃分析(PROSPERO CRD420251126926),检索PubMed、Embase和Cochrane图书馆至2025年8月31日,纳入12项研究共4537例接受PCI的心源性休克或心脏骤停后患者,比较辅助坎格瑞洛与口服P2Y12抑制剂。
- 全因死亡率:坎格瑞洛组较常规治疗降低(RR 0.90;95%CI 0.82–0.98);心源性休克亚组显著降低(RR 0.86;95%CI 0.78–0.96),心脏骤停亚组无显著差异(RR 0.94;95%CI 0.74–1.18)。
- 心血管死亡无显著差异(RR 0.96;95%CI 0.76–1.22);支架血栓无显著差异(RR 0.72;95%CI 0.34–1.53);心肌梗死无显著差异(RR 0.83;95%CI 0.44–1.57);卒中无显著差异(RR 1.83;95%CI 0.89–3.74)。
- PCI后TIMI 3级血流达成率:坎格瑞洛组更高(RR 1.14;95%CI 1.01–1.29)。
- 大出血:总体未显著增加(RR 1.37;95%CI 0.95–1.97),但在对照研究中风险相对升高(RR 1.50;95%CI 1.10–2.05)。
- 亚组分析:使用机械循环支持的心源性休克患者、院外心脏骤停患者及接受目标温度管理的心脏骤停患者,所有终点均无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入12项研究共4537例患者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对接受PCI的心源性休克患者,若口服P2Y12抑制剂给药不可行,作者认为静脉坎格瑞洛可作为有价值的替代选择。
- 对心脏骤停后接受PCI的患者,坎格瑞洛对全因死亡率无显著影响(RR 0.94;95%CI 0.74–1.18),是否使用需权衡出血风险。
- 使用坎格瑞洛时需注意大出血风险:总体未显著增加,但在对照研究中风险相对升高(RR 1.50;95%CI 1.10–2.05)。
- 作者结论:坎格瑞洛的总体临床获益尚待大规模随机试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence for cangrelor in critically ill patients remains extremely limited, despite heightened thrombotic risk from delayed oral P2Y12 inhibitor effects post- percutaneous coronary intervention (PCI). We aim to assess intravenous (IV) cangrelor’s efficacy and safety in patients with cardiogenic shock (CS) or post-cardiac arrest (CA) undergoing PCI. METHODS: This systematic review and meta-analysis (PROSPERO number: CRD420251126926) searched PubMed, Embase, and the Cochrane library to identify studies comparing adjunctive cangrelor with oral P2Y12 inhibitor during PCI in patients with CS or CA, published up until August 31, 2025. Efficacy endpoints included all-cause mortality, cardiovascular (CV) mortality, stent thrombosis, myocardial infarction (MI), stroke, and TIMI 3 flow achievement; safety endpoints were major and minor bleeding episodes. RESULTS: A total of 12 studies including 4,537 patients were identified. Compared with the conventional treatment, adjunctive cangrelor reduced all-cause mortality overall (RR, 0.90; 95% CI, 0.82–0.98); the effect was significant in CS (RR, 0.86; 95% CI, 0.78–0.96) but not in CA (RR, 0.94; 95% CI, 0.74–1.18). No significant differences were observed in CV mortality (RR, 0.96; 95% CI, 0.76–1.22), stent thrombosis (RR, 0.72; 95% CI, 0.34–1.53), MI (RR, 0.83; 95% CI; 0.44–1.57), or stroke (RR, 1.83; 95% CI, 0.89–3.74). In addition, cangrelor was associated with higher rates of post-PCI TIMI 3 flow (RR, 1.14; 95% CI, 1.01–1.29). Major bleeding was not significantly increased overall (RR, 1.37; 95% CI, 0.95–1.97), but in controlled studies the risk was relatively increased (RR, 1.50; 95% CI, 1.10–2.05). Subgroup analyses of patients with CS supported by mechanical circulatory support, out-of-hospital CA, and CA managed with targeted temperature management showed no significant differences in clinical outcomes across all endpoints. CONCLUSIONS: IV cangrelor was associated with reduced mortality following PCI in hemodynamically unstable patients, with the most pronounced benefit observed in those with CS, alongside improved coronary flow. These findings support its role as a valuable alternative when oral P2Y12 inhibitor administration is not feasible, pending confirmation of overall clinical benefit in large-scale randomized trials.
参考来源
- Hendrianus H, Jeong YH, Lee SY, et al. Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Crit Care. 2025. PMID: 41457245. doi:10.1186/s13054-025-05812-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。